Dexcom Launches First Over-the-Counter Continuous Glucose Monitor in the U.S.

Pressing a grey plastic applicator against the back of the upper arm inserts a sterile, hair-thin sensor filament just under the skin. The applicator clicks, releases, and is discarded, leaving a small patch that transmits glucose readings to a smartphone via Bluetooth every fifteen minutes. On August 26, 2024, Dexcom launched this device, the Stelo Glucose Biosensor, making it the first continuous glucose monitor available in the United States without a prescription. The launch marks a pivot in how medical sensor technology is distributed and paid for, bypassing both the traditional clinical prescription pathway and the health insurance reimbursement system.

For more than two decades, continuous glucose monitors (CGMs) have been heavily restricted. Regulators and insurers treated them strictly as prescription hardware, developed primarily for patients with type one diabetes or insulin-dependent type two diabetes. For these patients, real-time glucose tracking is a safety tool to prevent severe hypoglycemia, which is a life-threatening drop in blood sugar. Early sensors featured loud, urgent alarms to wake sleeping patients or alert caregivers to sudden shifts in glucose levels.

The Stelo biosensor strips away these medical-grade alarms to target a different clinical population. The Food and Drug Administration cleared the device for adults aged twenty-one and older who do not use insulin. This cohort includes individuals with type two diabetes who manage their condition with oral medications or lifestyle modifications, as well as people with prediabetes who want to monitor their metabolic responses.

By removing the prescription requirement, the manufacturer bypasses a major administrative hurdle. Under the traditional prescription model, patients must schedule clinical visits, secure a diagnosis that meets strict insurance criteria, obtain prior authorization, and fill the prescriptions at pharmacies. For patients who do not require insulin, health insurance coverage for CGMs is rarely approved. This leaves patients to pay out-of-pocket retail prices that can exceed three hundred dollars per month. The over-the-counter model bypasses this clinical and administrative pipeline, allowing consumers to purchase the hardware directly online.

Clinical utility for non-insulin users

The clinical rationale for extending continuous glucose monitoring to non-insulin-using populations rests on the utility of immediate biofeedback. According to federal health data, approximately thirty-eight million Americans have diabetes, and about ninety-five percent of them have type two diabetes. The vast majority of these individuals do not take insulin, relying instead on oral medications, dietary choices, and regular exercise to manage their blood sugar levels.

Historically, these patients monitored their glucose using finger-stick blood meters. These devices provide a static data point at the moment of the test, offering little context. A patient might see a high reading two hours after a meal but cannot tell whether their blood sugar is rising, falling, or plateauing.

In contrast, a continuous sensor reveals the entire glycemic curve. It shows the velocity and height of a glucose spike after a specific meal, and the subsequent rate of clearance as the body processes the carbohydrates. This real-time feedback operates as a behavioral tool. A patient can observe how a brisk walk immediately after eating dampens a glucose spike, or how poor sleep elevates baseline readings the following morning.

Clinical studies suggest that this continuous visibility supports sustained behavior change. When patients see the immediate metabolic consequences of their choices, they are more likely to adhere to dietary changes and increase their physical activity. Over time, these lifestyle adjustments help lower hemoglobin A1c levels, reduce the risk of long-term diabetic complications, and potentially delay the need for insulin therapy.

Market dynamics and pricing

The commercial strategy for the Stelo sensor is centered on direct-to-consumer pricing. Dexcom has priced the hardware at ninety-nine dollars for a pack of two sensors. Because each sensor has a wear time of fifteen days, a single pack provides a thirty-day supply of continuous monitoring. For consumers who opt for a recurring monthly subscription, the price decreases to eighty-nine dollars per month.

This pricing is notable when compared to the existing prescription CGM market, where out-of-pocket costs for uninsured patients can be prohibitive. By establishing a flat, predictable cash price, the manufacturer is targeting a large and growing self-pay market. The fifteen-day wear time also represents a technical adjustment from the company's flagship prescription device, the Dexcom G7, which is rated for ten days of wear. This extended battery and sensor life reduces the monthly hardware requirement from three sensors to two, lowering manufacturing and shipping costs.

The launch of Stelo initiates a broader competitive race in the consumer metabolic health space. Abbott, Dexcom's primary competitor in the glucose monitoring market, is preparing its own over-the-counter systems, known as Lingo and Libre Rio, which also received FDA clearance. As these major medical device manufacturers enter the consumer arena, they will compete not only with each other but also with digital health startups that have spent years packaging prescription CGMs with proprietary software overlays for healthy consumers.

For healthcare providers, the availability of over-the-counter continuous glucose monitors presents both an opportunity and a practical challenge. Clinicians will no longer need to write prescriptions or struggle with insurance paperwork for their non-insulin patients who want to use this technology. However, they must now prepare to interpret high-volume glucose data brought in by motivated patients during routine office visits. The success of the over-the-counter category will ultimately depend on how effectively patients and their care teams can translate these millions of data points into actionable, everyday health decisions.